Journal of Pharmacovigilance

Confluence of Artificial Intelligence and Pharmacovigilance Revolutionizing Drug Safety Surveillance

Masato Yoshizawa^* Department of Pharmacy, Shanxi Children's Hospital, Taiyuan, China
^*Correspondence: Masato Yoshizawa, Department of Pharmacy, Shanxi Children's Hospital, Taiyuan, China, Email:

Received: 31-Oct-2023, Manuscript No. JP-22-23991; Editor assigned: 02-Nov-2023, Pre QC No. JP-22-23991(PQ); Reviewed: 16-Nov-2023, QC No. JP-22-23991; Revised: 23-Nov-2023, Manuscript No. JP-22-23991(R); Published: 30-Nov-2023, DOI: 10.35248/2329-6887.23.11.464

About the Study

Pharmacovigilance is a critical component of drug development and post-market surveillance, focusing on the monitoring and assessment of drug safety. As the pharmaceutical industry continues to advance, the need for more efficient and accurate methods of pharmacovigilance becomes increasingly apparent. Artificial Intelligence (AI) has emerged as a powerful tool in this regard, revolutionizing drug safety surveillance by enhancing the detection and management of adverse events associated with pharmaceutical products. This article explores how the confluence of AI and pharmacovigilance is reshaping drug safety surveillance, offering more timely and comprehensive insights into the risks and benefits of medications [1].

Pharmacovigilance derived from the words "pharmakon" (drug) and "vigilare" (to keep watch), is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. It plays a significant role in ensuring that drugs on the market are safe and effective for patients. Traditionally, pharmacovigilance relies on the collection and analysis of data from various sources, such as healthcare professionals, patients, and regulatory agencies. The primary goal is to identify Adverse Drug Reactions (ADRs), evaluate their severity, and assess the overall benefit-risk profile of pharmaceutical products [2,3].

While traditional pharmacovigilance methods have been instrumental in identifying and managing ADRs, they have certain limitations. These limitations include:

• A significant proportion of adverse events go unreported, leading to a lack of comprehensive data.

• Reporting and analyzing ADRs can be a time-consuming process, which may delay necessary interventions.

• The increasing volume of healthcare data makes it challenging to manually sift through the information effectively.

• Traditional methods are less efficient at detecting emerging safety signals in vast datasets.

• Traditional pharmacovigilance often lacks access to realworld evidence that can provide a more comprehensive view of drug safety [4-6].

Artificial Intelligence offers a solution to the limitations of traditional pharmacovigilance. AI systems can analyze vast amounts of data at unprecedented speeds, enabling them to detect safety signals and assess ADRs more effectively [7]. Here's how AI is revolutionizing drug safety surveillance:

• AI can process electronic health records, social media posts, and other unstructured data sources to identify potential ADRs and safety signals.

• Natural Language Processing (NLP) algorithms can extract relevant information from text data, making it easier to identify adverse events mentioned in clinical narratives and social media discussions.

• Machine learning models can continuously monitor and detect safety signals, even from large and diverse datasets, in real-time [8].

• AI can predict potential ADRs and their severity, aiding in risk assessment and early intervention.

• AI can help integrate real-world evidence into pharmacovigilance, offering a more comprehensive understanding of drug safety and effectiveness in diverse patient populations.

• AI can automate routine tasks in pharmacovigilance, reducing the burden on human resources and improving overall efficiency [9-10].

While AI holds immense potential in revolutionizing pharmacovigilance, it also presents challenges and ethical considerations. Data privacy, bias in AI algorithms, and ensuring transparency and accountability are critical concerns in the field.

Conclusion

The confluence of Artificial Intelligence and pharmacovigilance is transforming drug safety surveillance by providing more efficient, timely, and comprehensive insights into the risks and benefits of pharmaceutical products. By harnessing the power of AI, pharmacovigilance is better equipped to detect safety signals, predict adverse events, and integrate real-world evidence into its assessments. However, as this technological revolution continues, it is significant to address ethical concerns and ensure that AI is employed responsibly to enhance drug safety and patient outcomes. The future of pharmacovigilance lies in the synergy between human expertise and AI capabilities, promising safer medications and improved patient care.

References

1. Avorn J. Learning about the safety of drugs—a half-century of evolution. N Engl J Med. 2011;365(23):2151-2153.

   [Crossref] [Google Scholar] [PubMed]

2. Babigumira JB, Stergachis A, Choi HL, Dodoo A, Nwokike J, Garrison LP. A framework for assessing the economic value of pharmacovigilance in low-and middle-income countries. Drug Saf. 2014;37:127-134.

   [Crossref] [Google Scholar] [PubMed]

3. Mirbaha F, Shalviri G, Yazdizadeh B, Gholami K, Majdzadeh R. Perceived barriers to reporting adverse drug events in hospitals: a qualitative study using theoretical domains framework approach. Implement Sci. 2015;10:1-10.

   [Crossref] [Google Scholar] [PubMed]

4. Olsson S, Pal SN, Stergachis A, Couper M. Pharmacovigilance activities in 55 low-and middle-income countries: a questionnaire-based analysis. Drug Saf. 2010;33:689-703.

   [Crossref] [Google Scholar] [PubMed]

5. Olsson S, Pal SN, Dodoo A. Pharmacovigilance in resource-limited countries. Expert Rev Clin Pharmacol. 2015;8(4):449-460.

   [Crossref] [Google Scholar] [PubMed]

6. Radecka A, Loughlin L, Foy M, de Ferraz Guimaraes MV, Sarinic VM, Di Giusti MD, et al. Enhancing pharmacovigilance capabilities in the EU regulatory network: the SCOPE joint action. Drug Saf. 2018;41:1285-1302.

   [Crossref] [Google Scholar] [PubMed]

7. Raschi E, Fusaroli M, La Placa M, Ardizzoni A, Zamagni C, Poluzzi E, et al. Skin toxicities with cyclin-dependent kinase 4/6 inhibitors in breast cancer: signals from disproportionality analysis of the FDA adverse event reporting system. Am J Clin Dermatol. 2021:1-9.

   [Crossref] [Google Scholar] [PubMed]

8. Dickler MN, Tolaney SM, Rugo HS, Cortés J, Diéras V, Patt D, et al. MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2− metastatic breast cancer. Clin Cancer Res. 2017;23(17):5218-5224.

   [Crossref] [Google Scholar] [PubMed]

9. Braal CL, Jongbloed EM, Wilting SM, Mathijssen RH, Koolen SL, Jager A. Inhibiting CDK4/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences. Drugs. 2021;81:317-331.

   [Crossref] [Google Scholar] [PubMed]

10. Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci. 2013;10(7):796.

    [Crossref] [Google Scholar] [PubMed]